AbbVie Inc.

ABBV
Pharmaceutical preparations
Last filing · Quarter 2 · Jun 30, 2026
Financial Statements Ratios
Export XLSX
Statement
Income StatementBalance SheetCash Flow
Period
Annual Quarterly
Order

29 more quarters with Pro

AbbVie Inc. back to 2013, every line as filed.

Create a free account
USD ($)
$ in Millions 		Jun 30, 2026Mar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024Jun 30, 2024Mar 31, 2024Sep 30, 2023Jun 30, 2023Mar 31, 2023Sep 30, 2022Jun 30, 2022Mar 31, 2022Sep 30, 2021Jun 30, 2021Mar 31, 2021Sep 30, 2020Jun 30, 2020Mar 31, 2020Sep 30, 2019Jun 30, 2019Mar 31, 2019Sep 30, 2018Jun 30, 2018Mar 31, 2018Sep 30, 2017Jun 30, 2017Mar 31, 2017Sep 30, 2016Jun 30, 2016Mar 31, 2016Sep 30, 2015Jun 30, 2015Mar 31, 2015Sep 30, 2014Jun 30, 2014Mar 31, 2014Sep 30, 2013Jun 30, 2013Mar 31, 2013
Statement of Cash Flows [Abstract]
                                         
Net earnings
$ 3,616
$ 697
$ 188
$ 941
$ 1,289
$ 1,564
$ 1,373
$ 1,372
$ 1,781
$ 2,027
$ 241
$ 3,952
Cash flows from operating activities
                                         
Adjustments to reconcile net earnings to net cash from operating activities:
                                         
Depreciation
194
188
192
186
181
191
184
183
196
190
179
181
Amortization of intangible assets
17
1,748
19
19
1,858
19
19
1,891
20
21
1,948
20
Deferred income taxes
(195)
137
193
(272)
(28)
(277)
(16)
(389)
(863)
(368)
(267)
(621)
Change in fair value of contingent consideration liabilities
1,518
2,387
776
2,795
1,518
1,356
1,476
660
8
1,552
1,872
(214)
Payments of contingent consideration liabilities
(1,062)
(722)
(776)
(859)
(549)
(580)
(485)
(391)
(407)
-
-
-
Stock-based compensation
166
444
209
179
410
181
218
348
130
179
313
126
Acquired IPR&D and milestones
291
744
2,680
823
248
82
937
164
66
280
150
40
Gain on divestitures
-
-
-
-
-
-
-
-
-
-
-
-
Non-cash litigation reserve adjustments, net of cash payments
(64)
150
(319)
(21)
(729)
314
27
-
(87)
(118)
-
71
Impairment of Intangible Assets (Excluding Goodwill)
-
-
847
-
-
-
-
0
2,114
-
710
770
Upfront costs and milestones related to collaborations
-
-
-
-
-
-
-
-
-
-
-
-
Devaluation loss related to Venezuela
-
-
-
-
-
-
-
-
-
-
-
-
Other, net
4
(22)
(90)
79
17
(22)
(8)
(45)
(46)
(45)
(128)
(65)
Changes in operating assets and liabilities, net of acquisitions:
                                         
Accounts receivable
(1,369)
87
(156)
(17)
(1,479)
344
178
(702)
2
(80)
(195)
357
Accounts and other receivables
-
-
-
-
-
-
-
-
-
-
-
-
Inventories
(143)
(184)
2
(56)
(155)
(64)
(52)
(75)
(55)
(273)
(185)
(17)
Prepaid expenses and other assets
(188)
(150)
88
371
(628)
152
25
284
109
452
(167)
(74)
Accounts payable and other liabilities
1,202
(1,594)
1,730
515
(696)
267
(1,699)
362
2,554
1,572
(465)
778
Income tax assets and liabilities, net
(2,223)
(81)
(411)
(1,375)
378
51
(1,834)
378
33
(1,119)
187
294
Cash flows from operating activities
3,436
3,829
7,024
5,153
1,635
5,447
2,271
4,040
7,574
6,319
4,193
7,602
Cash flows from investing activities
                                         
Acquisitions of businesses, net of cash acquired
-
0
-
-
(204)
(8,294)
-
(9,199)
-
-
-
-
Other acquisitions and investments, net of cash acquired
(824)
(266)
(2,802)
(940)
(334)
(199)
(843)
(190)
(157)
(160)
(353)
(100)
Acquisitions and investments
-
-
-
-
-
-
-
-
-
-
-
-
Acquisitions of property and equipment
(322)
(265)
(381)
(269)
(235)
(249)
(241)
(193)
(219)
(178)
(175)
(177)
Transfers to restricted cash
-
-
-
-
-
-
-
-
-
-
-
-
Purchases of investment securities
-
-
(7)
(12)
(10)
(24)
(16)
(6)
(8)
(16)
(19)
(17)
Sales and maturities of investment securities
-
-
3
7
32
507
3
6
5
14
22
1,410
Other, net
(51)
(43)
(77)
33
16
3
(5)
(6)
10
(1)
26
170
Cash flows from investing activities
(1,197)
(574)
(3,264)
(1,181)
(735)
(8,256)
(1,102)
(9,588)
(369)
(341)
(499)
1,286
Cash flows from financing activities
                                         
Net change in commercial paper borrowings with original maturities of three months or less
-
(499)
(550)
(44)
1,593
-
-
-
-
-
-
-
Proceeds from issuance of other short-term borrowings
-
-
791
4,007
0
-
-
5,008
-
-
-
-
Repayments of other short-term borrowings
-
(2,000)
(2,007)
-
0
-
(3)
(5,005)
-
-
-
-
Proceeds from issuance of long-term debt
-
7,991
-
-
3,994
-
-
14,963
-
-
0
-
Net change in short-term borrowings
-
-
-
-
-
-
-
-
-
-
-
-
Repayments of long-term debt
(2,000)
0
(9)
(3,754)
(3,026)
(403)
(3,345)
(103)
(2)
(1,002)
(1,351)
(2,701)
Debt issuance costs
-
-
-
(3)
(20)
-
-
(99)
-
-
-
-
Repayments of long-term debt and finance lease obligations
-
-
-
-
-
-
-
-
-
-
-
-
Dividends paid
(3,070)
(3,086)
(2,911)
(2,910)
(2,925)
(2,751)
(2,750)
(2,772)
(2,627)
(2,625)
(2,661)
(2,504)
Purchases of treasury stock
(9)
(1,489)
(4)
(12)
(961)
(17)
(9)
(1,324)
(4)
(10)
(1,955)
(4)
Proceeds from the exercise of stock options
-
-
63
5
56
67
10
127
36
48
65
11
Payments of contingent consideration liabilities
-
-
-
-
-
-
-
0
(94)
(330)
(311)
(335)
Net transactions with Abbott Laboratories, excluding noncash items
-
-
-
-
-
-
-
-
-
-
-
-
Other, net
25
2
37
1
31
32
-
24
30
(1)
21
15
Cash flows from financing activities
(5,054)
919
(4,590)
(2,710)
(1,258)
(3,072)
(6,097)
10,819
(2,661)
(3,920)
(6,192)
(5,518)
Effect of exchange rate changes on cash and equivalents
(7)
(12)
(8)
30
9
8
(9)
(18)
(16)
(10)
8
(59)
Net decrease in cash and equivalents
-
-
-
-
-
-
-
-
-
-
-
-
Net change in cash and equivalents
(2,822)
4,162
(838)
1,292
(349)
(5,873)
(4,937)
5,253
4,528
2,048
(2,490)
3,311
Supplemental schedule of non-cash investing and financing activities
                                         
Issuance of common shares associated with acquisitions of businesses
-
-
-
-
-
-
-
-
-
-
-
-